Kevin T. Conroy

Kevin T. Conroy (chief executive) discloses dealings in 6 companies, chiefly Exact Sciences Corp, Epizyme, Inc. and Align Technology Inc. Over a trading history stretching from 18 February 2015 to 23 September 2026, the count stands at 57 filings.

Both buying and selling appear: 1 purchase worth €943k, against 7 sales worth €8.2M. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 20 share grants and 23 option exercises.

On 25 September 2026 came the latest disclosure, a share grant for €4.8M in Abbott Laboratories. The most recent open-market purchase was published on 13 November 2024, 704 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.